Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

KIT-D816V oncogenic activity is controlled by the juxtamembrane docking site Y568-Y570.

Chaix A, Arcangeli ML, Lopez S, Voisset E, Yang Y, Vita M, Letard S, Audebert S, Finetti P, Birnbaum D, Bertucci F, Aurrand-Lions M, Dubreuil P, De Sepulveda P.

Oncogene. 2014 Feb 13;33(7):872-81. doi: 10.1038/onc.2013.12. Epub 2013 Feb 18.

PMID:
23416972
2.

The activation loop tyrosine 823 is essential for the transforming capacity of the c-Kit oncogenic mutant D816V.

Agarwal S, Kazi JU, Mohlin S, Påhlman S, Rönnstrand L.

Oncogene. 2015 Aug 27;34(35):4581-90. doi: 10.1038/onc.2014.383. Epub 2014 Dec 1.

PMID:
25435369
3.

The c-Kit/D816V mutation eliminates the differences in signal transduction and biological responses between two isoforms of c-Kit.

Pedersen M, Rönnstrand L, Sun J.

Cell Signal. 2009 Mar;21(3):413-8. doi: 10.1016/j.cellsig.2008.11.008. Epub 2008 Nov 17.

PMID:
19049823
4.

PI3 kinase is indispensable for oncogenic transformation by the V560D mutant of c-Kit in a kinase-independent manner.

Lindblad O, Kazi JU, Rönnstrand L, Sun J.

Cell Mol Life Sci. 2015 Nov;72(22):4399-407. doi: 10.1007/s00018-015-1944-9. Epub 2015 Jun 4.

PMID:
26040420
5.

EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation.

Pan J, Quintás-Cardama A, Kantarjian HM, Akin C, Manshouri T, Lamb P, Cortes JE, Tefferi A, Giles FJ, Verstovsek S.

Blood. 2007 Jan 1;109(1):315-22. Epub 2006 Aug 15.

6.

The D816V mutation of c-Kit circumvents a requirement for Src family kinases in c-Kit signal transduction.

Sun J, Pedersen M, Rönnstrand L.

J Biol Chem. 2009 Apr 24;284(17):11039-47. doi: 10.1074/jbc.M808058200. Epub 2009 Mar 5.

7.

The antitumor activity of homoharringtonine against human mast cells harboring the KIT D816V mutation.

Jin Y, Lu Z, Cao K, Zhu Y, Chen Q, Zhu F, Qian C, Pan J.

Mol Cancer Ther. 2010 Jan;9(1):211-23. doi: 10.1158/1535-7163.MCT-09-0468. Epub 2010 Jan 6.

8.

The PI3-kinase isoform p110δ is essential for cell transformation induced by the D816V mutant of c-Kit in a lipid-kinase-independent manner.

Sun J, Mohlin S, Lundby A, Kazi JU, Hellman U, Påhlman S, Olsen JV, Rönnstrand L.

Oncogene. 2014 Nov 13;33(46):5360-9. doi: 10.1038/onc.2013.479. Epub 2013 Nov 11.

PMID:
24213578
9.

Necessity of tyrosine 719 and phosphatidylinositol 3'-kinase-mediated signal pathway in constitutive activation and oncogenic potential of c-kit receptor tyrosine kinase with the Asp814Val mutation.

Hashimoto K, Matsumura I, Tsujimura T, Kim DK, Ogihara H, Ikeda H, Ueda S, Mizuki M, Sugahara H, Shibayama H, Kitamura Y, Kanakura Y.

Blood. 2003 Feb 1;101(3):1094-102. Epub 2002 Sep 12.

10.

Autoinhibition of the kit receptor tyrosine kinase by the cytosolic juxtamembrane region.

Chan PM, Ilangumaran S, La Rose J, Chakrabartty A, Rottapel R.

Mol Cell Biol. 2003 May;23(9):3067-78.

11.

Oncogenic mutation in the Kit receptor tyrosine kinase alters substrate specificity and induces degradation of the protein tyrosine phosphatase SHP-1.

Piao X, Paulson R, van der Geer P, Pawson T, Bernstein A.

Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14665-9.

13.

Neoplasia driven by mutant c-KIT is mediated by intracellular, not plasma membrane, receptor signaling.

Xiang Z, Kreisel F, Cain J, Colson A, Tomasson MH.

Mol Cell Biol. 2007 Jan;27(1):267-82. Epub 2006 Oct 23.

14.

In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit.

Corbin AS, Demehri S, Griswold IJ, Wang Y, Metcalf CA 3rd, Sundaramoorthi R, Shakespeare WC, Snodgrass J, Wardwell S, Dalgarno D, Iuliucci J, Sawyer TK, Heinrich MC, Druker BJ, Deininger MW.

Blood. 2005 Jul 1;106(1):227-34. Epub 2005 Mar 3.

15.

Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells.

Gabillot-Carré M, Lepelletier Y, Humbert M, de Sepuvelda P, Hamouda NB, Zappulla JP, Liblau R, Ribadeau-Dumas A, Machavoine F, Letard S, Baude C, Hermant A, Yang Y, Vargaftig J, Bodemer C, Morelon E, Lortholary O, Recher C, Laurent G, Dy M, Arock M, Dubreuil P, Hermine O.

Blood. 2006 Aug 1;108(3):1065-72. Epub 2006 Apr 4.

16.

STAT3 activation is required for Asp(816) mutant c-Kit induced tumorigenicity.

Ning ZQ, Li J, McGuinness M, Arceci RJ.

Oncogene. 2001 Jul 27;20(33):4528-36.

17.

C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice.

Wang YY, Zhao LJ, Wu CF, Liu P, Shi L, Liang Y, Xiong SM, Mi JQ, Chen Z, Ren R, Chen SJ.

Proc Natl Acad Sci U S A. 2011 Feb 8;108(6):2450-5. doi: 10.1073/pnas.1019625108. Epub 2011 Jan 24.

18.

Analysis of KIT mutations in sporadic and familial gastrointestinal stromal tumors: therapeutic implications through protein modeling.

Tarn C, Merkel E, Canutescu AA, Shen W, Skorobogatko Y, Heslin MJ, Eisenberg B, Birbe R, Patchefsky A, Dunbrack R, Arnoletti JP, von Mehren M, Godwin AK.

Clin Cancer Res. 2005 May 15;11(10):3668-77.

19.

Germline-activating mutation in the kinase domain of KIT gene in familial gastrointestinal stromal tumors.

Isozaki K, Terris B, Belghiti J, Schiffmann S, Hirota S, Vanderwinden JM.

Am J Pathol. 2000 Nov;157(5):1581-5.

20.

Signal transduction by several KIT juxtamembrane domain mutations.

Casteran N, De Sepulveda P, Beslu N, Aoubala M, Letard S, Lecocq E, Rottapel R, Dubreuil P.

Oncogene. 2003 Jul 24;22(30):4710-22.

PMID:
12879016

Supplemental Content

Support Center